Showing results (51-60 of 76) with videos related to
Sort By:
Pageof 8
Plos One|December 19, 2008
Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02Meta Roestenberg, Ed Remarque, Erik de Jonge, et al.Vaccine|April 19, 2016
Strain-specific Plasmodium falciparum multifunctional CD4(+) T cell cytokine expression in Malian children immunized with the FMP2.1/AS02A vaccine candidateShawna F Graves, Bourema Kouriba, Issa Diarra, et al.Journal of Clinical Microbiology|June 7, 2003
Devices for rapid diagnosis of Malaria: evaluation of prototype assays that detect Plasmodium falciparum histidine-rich protein 2 and a Plasmodium vivax-specific antigenJ Russ Forney, Chansuda Wongsrichanalai, Alan J Magill, et al.Plos Clinical Trials|November 25, 2006
Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib dose-escalation trial in Kenyan childrenMark R Withers, Denise McKinney, Bernhards R Ogutu, et al.The Lancet. Infectious Diseases|January 5, 2016
Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a studyOlga De Santis, Régine Audran, Emilie Pothin, et al.The Lancet. Infectious Diseases|January 18, 2011
Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trialAlly Olotu, John Lusingu, Amanda Leach, et al.The New England Journal of Medicine|December 10, 2008
Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of agePhilip Bejon, John Lusingu, Ally Olotu, et al.Plos Neglected Tropical Diseases|February 27, 2016
Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and EfficacyJason W Bennett, Anjali Yadava, Donna Tosh, et al.Vaccine|April 20, 2007
Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of ResearchMark E Polhemus, Alan J Magill, James F Cummings, et al.Malaria Journal|January 25, 2013
Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01Nekoye Otsyula, Evelina Angov, Elke Bergmann-Leitner, et al.Pageof 8